Stockwinners Market Radar for March 05, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:21 EST Lantheus director sells $6.13M in common stock - In a regulatory filing, Lantheus disclosed that its director Mary Anne Heino sold 93.9K shares of common stock on March 4th in a total transaction size of $6.13M.

20:38 EST Cathie Wood's ARK Investment bought 80K shares of Tesla today

19:50 EST Aptevo Therapeutics trading halted, news pending

18:29 EST Entravision discloses Meta winding down authorized sales partner program - In a regulatory filing, Entravision (EVC) stated: "On March 4, 2024, the company received a communication from Meta Platforms (META) that it intends to wind down its authorized sales partner program globally and end its relationship with all of its ASPs, including the company, by July 1, 2024. For full year 2023, Meta's ASP program represented $586.4M of the company's $1.1B of total consolidated revenue. The company has initiated a review of its operating strategy and cost structure and will provide an update on associated plans as soon as practicable."

18:17 EST Vincerx Pharma to present three posters at AACR - Vincerx Pharma "announced it will present three posters at the American Association for Cancer Research, AACR, Annual Meeting 2024, taking place in San Diego, CA, from April 5 - 10, 2024. Vincerx will also share clinical data for VIP236 at the conference." CEO Ahmed Hamdy stated: "We are extremely pleased to highlight the continued development of our next-generation VersAptx(TM) bioconjugation platform in these three abstract/poster presentations. In addition to the preclinical results of our VersAptx platform, our SMDC poster will also present, for the first time, early clinical results for VIP236. To date, 20 patients with relapsed/refractory advanced or metastatic solid tumors have been treated with two different dosing schedules of VIP236. The poster will summarize preliminary safety, efficacy, and pharmacokinetic results from this first-in-human, dose-escalation study."

18:09 EST NextCure's treatment of AML granted FDA orphan designation - According to a post on the FDA's website, NextCure's treatment of AML was granted orphan designation. Reference Link

18:07 EST Microsoft ends support for Windows Subsystem for Android - Microsoft (MSFT) said it is ending support for the Windows Subsystem for Android (GOOG). As a result, the Amazon Appstore (AMZN) on Windows and all applications and games dependent on WSA will no longer be supported beginning March 5, 2025. Until then, technical support will remain available to customers. Customers that have installed the Amazon Appstore or Android apps prior to March 5, 2024, will continue to have access to those apps through the deprecation date of March 5, 2025. Reference Link

17:57 EST General Dynamics awarded $239.3M Air Force contract - General Dynamics was awarded a $239.3M ceiling, indefinite-delivery/indefinite-quantity contract for the U.S. Battlefield Information Collection and Exploitation System, trusted network environment cross domain solution. This contract provides for services to sustain and enhance current coalition operations by providing the capability to share information rapidly and securely while collaborating with allies, partner nations and emerging coalitions worldwide on disparate networks simultaneously at the secret releasable level. Work will be performed at various locations worldwide and is expected to be completed by February 28, 2029. This contract was a sole-source acquisition. The Secretary of the Air Force, Concepts Development and Management Contracting Office is the contracting activity.

17:40 EST Couchbase up 11% at $29.86 after Q4 earnings beat, above-consensus guidance

17:29 EST Verastem receives Orphan Drug Designation from FDA for avutometinib - Verastem Oncology announced that the FDA granted Orphan Drug Designation, or ODD, to avutometinib, a RAF/MEK clamp, alone or in combination with defactinib, a selective FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer, or LGSOC. Approximately 70% of LGSOC is associated with RAS/MAPK Pathway alterations including KRAS, NRAS HRAS, and other non-RAS associated mutations. Unfortunately, approximately 85% of patients with LGSOC experience recurrence of the disease. LGSOC is a highly recurrent, chemotherapy-resistant cancer, associated with slow tumor growth and high mortality rate. An estimated 6,000 women in the U.S. and 80,000 worldwide are living with this disease. LGSOC affects a younger patient population with bimodal peaks at ages 20-30 and 50-60 years of age and has a median survival of approximately ten years. The majority of patients experience severe pain and complications as the disease progresses. While chemotherapy is the standard of care for this disease, there are no treatments specifically approved by the FDA to treat LGSOC.

17:22 EST Franco-Nevada total GEO sales excluding Cobre Panama 480,000-540,000 - Sees FY24 precious metal GEO sales excluding Cobre Panama 360,000-400,000. The company said, "For both our 2024 guidance and 5-year outlook, when reflecting revenue from gold, silver, platinum, palladium, iron ore, oil and gas commodities to GEOs, we assumed the following prices: $1,950/oz Au, $22.50/oz Ag, $850/oz Pt, $900/oz Pd, $115/tonne Fe 62% CFR China, $75/bbl WTI oil and $2.50/mcf Henry Hub natural gas. In addition, we do not assume any other acquisitions and do not reflect any incremental revenue from additional contributions we may make to the Royalty Acquisition Venture with Continental as part of our remaining commitment of $69.8M. The 2024 guidance and 5-year outlook are based on public forecasts and other disclosure by the third-party owners and operators of our assets and our assessment thereof. We present our guidance in reference to GEO sales. For streams, our projected GEOs reflect GEOs we acquire from the operators of our assets and subsequently sell. Our GEO sales may differ from operators' production based on timing of deliveries, and are presented net of recovery and payability factors. We assume Cobre Panama will remain in P&SM through 2024 and have not included any contributions from the asset in our guidance. We expect an increase in GEO sales from the balance of our Precious Metal assets in 2024. The net increase reflects initial contributions from new mines including Tocantinzinho, Greenstone and Salares Norte. We are guiding towards lower GEOs from our Energy assets based on lower assumed oil and gas prices."

17:11 EST Twilio sees FY24 organic revenue growth of 5%-10% - As part of its announcement regarding the decision for its Segment business earlier today, the company announced it is targeting GAAP operating profitability by Q4 of FY25.

17:01 EST W&T Offshore sees FY24 total equivalents 12,417-14,592 MBoe/d - Sees FY24 oil production 5,100-5,800 MBbl.

16:46 EST Crowdstrike jumps 20% to $358 after Q4 earnings beat, above-consensus guidance

16:35 EST First Watch Restaurant announces co-founder Ken Pendery passes away - First Watch announced that co-founder and longtime leader Ken Pendery passed away on March 4 after a battle with Multiple System Atrophy, a rare neurological disorder.

16:33 EST Realtor.com, Zillow sign new rental listings syndication agreement - Realtor.com and Zillow announced a new agreement for Zillow to be the exclusive provider of multifamily rental listings on Realtor.com, generating additional exposure for listings to millions of renters. As part of the new agreement, multifamily rental listings with 25 or more units advertised on Zillow will also be displayed on Realtor.com. Renters who visit Realtor.com will have an enhanced experience with Zillow 3D Home tours, interactive floor plans, walkthrough videos and more, powered by Zillow's marketplace of listings. The data will complement Realtor.com's current rental content sourced from direct relationships with single-family and low-rise rentals landlords through its Avail platform, Internet Listing Services and property management companies, as well as the rental content that Realtor.com sources from multiple listing services nationwide.

16:31 EST Cboe Global Markets reports February trading volume - Reference Link

16:31 EST XPO: February LTL tonnage per day increased 3.5% vs. last year - XPO reported certain preliminary LTL segment operating metrics for February . LTL tonnage per day increased 3.5%, as compared with February 2023, attributable to a year-over-year increase of 5.8% in shipments per day and a decrease of 2.2% in weight per shipment.

16:29 EST Cerus affirms 2024 product revenue guidance - The company "expects full-year 2024 product revenue will be in the range of $172M to $175M. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8M to $10M."

16:27 EST Gritstone reduced workforce by 40% in February - In February 2024, Gritstone bio reduced its workforce by approximately 40% to reduce costs and preserve capital. The reduction primarily impacted employees associated with vaccine manufacturing and clinical infectious disease operations, who were not active in the ongoing Phase 2 study of GRANITE, Gritstone's personalized cancer vaccine. The reduction occurred approximately two weeks following the previously announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.

16:25 EST Core Scientific reports February bitcoin sold 952 vs. 1,114 last month - CEO Adam Sullivan says: "Owning our own infrastructure provides us with strategic flexibility to respond rapidly to dynamic market conditions. For example, we increased our self-mining hash rate by 300 petahash largely by redeploying earlier-generation miners. These miners had been replaced with more efficient S19j XP units in January, using newly activated capacity. Capitalizing on strong spot bitcoin pricing, quickly reactivating these miners boosted our hash rate and enhances our bitcoin earnings. From a capital expenditures perspective, we continue to manage our investments carefully to ensure our ongoing financial strength. To that end, we completed all miner payments due in 2024 for the S19j XPs and S21s we previously announced, enabling us to focus our remaining investments this year on new miner purchases and our organic infrastructure growth plans."

16:18 EST Vintage Wine Estates provides update on asset sales - Seth Kaufman, President and CEO of Vintage Wine Estates, states: "To reposition VWE as an omnichannel wine and cider company that offers the highest quality Super Premium+ products in the U.S., we are aggressively advancing on our top priorities to: improve profitability and build a strong go-to-market capability that supports differentiated brands, sell non-core assets to measurably reduce debt, and optimize operations to improve cash generation. We are actively executing against our planned roadmap to engage potential acquirers for our stand-alone DTC and certain production services businesses, in addition to other assets. This will generate needed focus and allow us to strategically deploy our resources to support a unique branded wine and cider business which we believe can offer accelerated top-line growth, gains in market share, expanded margins, and improved cash generation. We anticipate that selling these non-core assets with unfavorable cost structures will materially reduce operating expenses and help transform VWE into a much smaller, but more profitable business, that can consistently generate cash. And, perhaps most importantly, these actions can allow us to return our focus to developing and scaling unique brands that delight consumers with highly-rated wines and ciders."

16:17 EST flyExclusive announces $25M equity investment - flyExclusive "announced that it has entered into a securities purchase agreement with an investment vehicle managed by EnTrust Global pursuant to which the Investor purchased 25,000 shares of Series A Non-Convertible Redeemable Preferred Stock, par value of $0.0001 per share, at a purchase price of $1,000 per share. The Company received approximately $25 million in cash proceeds in connection with the transaction, which closed on March 4, 2024."

16:14 EST ChargePoint affirms positive adjusted EBITDA by Q4 of FY25 - The company states: "For the fourth quarter of fiscal year 2025 ending January 31, 2025, the Company reaffirms its goal to achieve positive non-GAAP Adjusted EBITDA."

16:10 EST Box expands collaboration with Microsoft with Azure OpenAI service - Box (BOX) announced a new integration with Microsoft (MSFT) Azure OpenAI Service to bring its advanced large language models to Box AI. The integration of Azure OpenAI Service enables Box customers to benefit from the most advanced AI models in the world, while bringing Box and Microsoft's enterprise-grade standards for security, privacy, and compliance to this groundbreaking technology. Box also announced that Box AI is generally available to customers on Enterprise Plus plans, starting today. Guided by its AI Principles, Box has built Box AI on the company's platform-neutral framework, allowing it to connect with today's most powerful large language models. By integrating with Azure OpenAI Service, Box is applying the most advanced intelligence models to its Content Cloud to further advance enterprise-grade AI. Microsoft and Box already help customers meet strict compliance requirements like FINRA, GxP, and FedRAMP. With today's announcement, they will also empower organizations across highly-regulated industries to leverage AI for new use cases."

16:07 EST Box authorizes expansion of stock buyback by $100M - On March 4, 2024, the Board of Directors authorized an expansion of its stock repurchase program by $100 million.

16:03 EST Crowdstrike to acquire Flow Security, terms not stated - CrowdStrike "announced it has agreed to acquire Flow Security, the industry's first and only cloud data runtime security solution. With this acquisition, CrowdStrike is setting the standard for modern cloud security with comprehensive real-time data protection spanning endpoint and cloud environments, delivering the only cloud data protection platform that secures data in all states, both at rest and in motion. With the acquisition of Flow Security, the CrowdStrike Falcon platform is poised to become the industry's most comprehensive data security platform. Following the closing of the acquisition, CrowdStrike plans to fully deliver native Flow Security DSPM capabilities in Falcon Cloud Security as part of the Falcon XDR platform, enabling customers to consolidate cloud point solutions and protect the entire cloud estate. Through this, CrowdStrike will provide visibility into critical cloud data flows, insight into how data interacts with applications, and the ability to detect when sensitive data is at risk or unintentionally leaving an environment. The purchase price will be paid predominantly in cash, with a portion delivered in the form of equity subject to vesting conditions. The proposed acquisition is expected to close during CrowdStrike's fiscal first quarter, subject to customary closing conditions."

16:02 EST Marpai announces agreement with regional organization based in the southeast - Marpai, an independent national Third-Party Administration, or TPA, announced that it has signed a three-year agreement to provide healthcare benefit services to a regional organization based in the southeast. The agreement commenced this month, and it is expected to bring at least 20,000 households by the end of 2024.

15:47 EST Coinbase says aware some users experiencing errors when transacting - Coinbase said it is aware that some users may be experiencing errors when transacting. "Our team is investigating this issue and will provide an update shortly," the company said. "Your assets are safe." Reference Link

15:38 EST Sophia Genetics SA trading halted, volatility trading pause

14:32 EST Citi CEO says sticking to full-year expense guidance - Citi CEO Jane Fraser, speaking at the RBC Capital Markets Conference, says the bank has been "swifter than expected" with its reorganization, that the bank is sticking to its full-year expense guidance and that the bank is "extremely comfortable" with its capital and liquidity.

13:26 EST Disney sees exceeding free cash flow guidance

13:25 EST Sandoz announces FDA approval for 'first and only denosumab biosimilars' - Sandoz, announced that the U.S. Food and Drug Administration approved Wyost and Jubbonti, which it calls "the first and only FDA-approved denosumab biosimilars, "to treat all indications of the reference medicines. Wyost is approved to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy. Jubbonti is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Keren Haruvi, President Sandoz North America, said: "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events, which are disease states that can profoundly reduce quality of life for patients. I am proud that Sandoz continues to pioneer access to these life-changing medicines for the patients who need them most."

13:18 EST Solowin Holdings Ltd trading resumes

13:13 EST Solowin Holdings Ltd trading halted, volatility trading pause

13:05 EST Target to launch and expand several owned brands in 2024 - In 2024, Target plans to launch and expand several owned brands to offer a wider range of options across categories, products and prices, the company announced. These include: dealworthy - The new brand is designed to give consumers "great value on nearly 400 everyday basics across apparel and accessories, beauty and essentials, electronics and home, starting under $1 with most items under $10"; up&up - Target relaunched its largest and most expansive essentials brand with new formulations, branding and packaging, plus hundreds of new everyday items in personal care, health, pet care, storage and more to round out the essentials assortment; Gigglescape - The new toy brand "sparks joy and imagination for kids and parents with an assortment of plush, books, toys, games and more rolling out in 2024 and beyond."

12:00 EST Yirendai falls -10.9% - Yirendai is down -10.9%, or -60c to $4.90.

12:00 EST Semrush falls -20.2% - Semrush is down -20.2%, or -$2.62 to $10.38.

12:00 EST Nuscale Power rises 18.4% - Nuscale Power is up 18.4%, or 72c to $4.62.

11:49 EST YouTube confirms loading issues, says 'working on a fix now' - YouTube said in an update: "We've seen reports of loading issues with YouTube, rest assured we're working on a fix now! Here's what you might be seeing: Empty Homepage and error message; Spinning wheel while scrolling on Shorts; Hitting a dead end while scrolling on Shorts. Let us know if you're experiencing any other types of issues, we'll provide updates here as soon as we have them." Reference Link

11:47 EST Meta 'aware' of issue impacting Facebook Login - Meta said in an update on its status page: "We are aware of an issue impacting Facebook Login. Our engineering teams are actively looking to resolve the issue as quickly as possible." Reference Link

11:14 EST Accenture to acquire Udacity, terms not disclosed - Accenture has agreed to acquire Udacity, which it calls "a digital education pioneer with deep expertise in the development and delivery of proprietary technology courses that blend the flexibility of online learning with the benefits of human instruction." Terms of the transaction were not disclosed. Udacity's team of more than 230 professionals will join Accenture LearnVantage, also announced today, which provides Accenture's clients with "comprehensive technology learning and training services that will help them reskill and upskill their people in technology, data and AI to reinvent their organizations and achieve greater business value," the company stated.

11:02 EST Planet Labs awarded contract for vessel detection, monitoring by NIWC Pacific - Planet Labs PBC announced its fully owned subsidiary, Planet Labs Federal Inc., was awarded a seven-figure contract by the Naval Information Warfare Center Pacific for vessel detection and monitoring over key areas of interest throughout the Pacific. The project will integrate both Planet's daily, global PlanetScope data and high-resolution SkySat data into the Department of Transportation's SeaVision platform, a web-based maritime situational awareness tool, the company said in a statement, adding that the contract includes fusion of technology from SynMax, a longtime Planet partner, who will provide vessel detection using their analytics technology over Planet data. "NIWC Pacific continually pushes the bounds of innovating and advancing unmatched and disruptive technology in support of their operations," said Jon Powers, Planet Federal's General Manager. "Planet possesses a unique broad area imagery collection of land and ocean areas in the Indo-Pacific, so it's exciting for us to contribute that unique capability to provide maritime insights in support of the SeaVision mission."

10:45 EST Datasea Inc trading halted, volatility trading pause

10:35 EST User reports indicate problems at Meta's Facebook, says Downdetector - Reference Link

10:01 EST Gap, Ambercycle announce efforts to advance textile-to-textile recycling - Gap and Ambercycle announced efforts to leverage textile-to-textile recycled materials in Athleta products. Athleta CEO, Chris Blakeslee added, Starting in 2026, Athleta - a Certified B Corporation - plans to become the first performance apparel brand to use cycora at scale. "As a mission-driven, B Corp-certified brand, Athleta is committed to reducing our environmental footprint by using recycled materials like cycora, which not only aligns with our values but also meets our uncompromising quality standards."

10:00 EST Crown Castle comments on 'unfounded' litigation brought by Ted Miller - Crown Castle commented on the litigation brought by Ted Miller and Boots Capital Management."The lawsuit brought by Mr. Miller is without merit and underscores that his activism campaign against Crown Castle is focused on his own self interests. These interests include, among other things, the appointment to the Board of himself and three of his handpicked nominees (including his son-in-law), and getting himself installed as a paid executive of the Company (with the title of executive chairman) after spending more than 22 years away. After previously calling for the Board to act with urgency, Mr. Miller is seeking as part of his litigation a Court order to, among other things, impede progress on the Company's ongoing CEO search and the strategic and operating review of its fiber business.In addition to advancing a self-serving agenda, impeding value-creation work that Mr. Miller claims to support, and being premised on a host of misleading assertions and outright inaccuracies, Mr. Miller's litigation seeks inappropriately to weaponize the Delaware Court of Chancery's recent decision in West Palm Beach Firefighters' Pension Fund v. Moelis & Co. in an attempt to gain an advantage in his proxy fight against the Company. Contrary to Mr. Miller's misleading allegations and distinct from Moelis, Elliott did not control Crown Castle before or as a result of the Cooperation Agreement. Today, the Crown Castle Board comprises 12 directors, 11 of whom are independent and only two of whom were appointed with input from Elliott. In truth, Mr. Miller is the one who seeks to dominate Crown Castle by having the Company name him executive chairman and put two of his associates and his son-in-law on the Board... The Board values feedback from all its shareholders and incorporates such feedback and suggestions in its deliberations. As such, all feedback, including the suggestions from Mr. Miller, are being considered as part of the Board's strategic review, which is focused on generating long-term value for all shareholders. Contrary to the Company's goals, Mr. Miller's proxy fight and his lawsuit seek above all else to prioritize his own interests, regardless of the consequences for Crown Castle's shareholders."

10:00 EST Albemarle falls -12.7% - Albemarle is down -12.7%, or -$16.95 to $116.25.

10:00 EST Fresenius Medical rises 10.2% - Fresenius Medical is up 10.2%, or $1.90 to $20.57.

10:00 EST Paymentus rises 19.9% - Paymentus is up 19.9%, or $3.25 to $19.60.

09:47 EST Kosmos falls -12.1% - Kosmos is down -12.1%, or -73c to $5.28.

09:47 EST Semrush falls -19.1% - Semrush is down -19.1%, or -$2.48 to $10.52.

09:47 EST Target rises 10.4% - Target is up 10.4%, or $15.72 to $166.21.

09:46 EST State Street sees Q1 expenses slightly better than prior guide - Sees expenses at higher end of up 1%1.5% y/y.

09:45 EST Fibrobiologics Inc trading resumes

09:41 EST Arisz Acquisition Corp trading resumes

09:38 EST Energem Corp trading resumes

09:33 EST Energem Corp trading halted, volatility trading pause

09:30 EST Tyler Technologies signs agreement with Maryland - Tyler Technologies announced that it has signed an agreement with the state of Maryland for Tyler's digital government solutions and services following a competitive procurement process. The five-year contract, which may be extended for five additional years at the state's option, builds upon the existing 12-year relationship between Maryland and Tyler's Digital Solutions Division. The agreement features a fully cloud-hosted infrastructure and includes delivering on Maryland's goals of secure, scalable, platform solutions accessible to all Marylanders.

09:29 EST Itron acquires software and services firm Elpis Squared, terms undisclosed - Itron announced it is expanding its Grid Edge Intelligence portfolio through the acquisition of Elpis Squared, an provider of software and services for utility grid operations, effective immediately...Combining Elpis Squared's RE Grid Suite with Itron's Grid Edge Intelligence solutions, which operate at utility scale across millions of endpoints, will accelerate key elements of Itron's product roadmap..."The acquisition of Elpis Squared strengthens Itron's Grid Edge Intelligence portfolio and will accelerate our product roadmap to create more value for our customers," said Don Reeves, senior vice president of Outcomes at Itron. "We look forward to enabling customers to solve critical operational challenges by embedding Itron's grid edge data and insights into utilities' grid planning and operations, addressing the energy transition." "We are excited to be acquired by Itron as we help utilities navigate a transforming grid with confidence," said Bryan Wright, CEO of Elpis Squared. "By adding our RE Grid Suite to Itron's Grid Edge Intelligence portfolio, Itron will catalyze the transformation of energy infrastructure and help utilities enhance resource productivity and create a sustainable, resilient and interconnected energy ecosystem."

09:23 EST Cadence acquires BETA CAE Systems for $1.24B in cash and stock - Cadence Design Systems announced it has entered into a definitive agreement to acquire BETA CAE Systems International AG, a system analysis platform provider of multi-domain, engineering simulation solutions. The addition of BETA CAE's proven technologies and talent will accelerate Cadence's Intelligent System Design strategy by expanding its multiphysics system analysis portfolio and enabling entry into the structural analysis segment, unlocking a multi-billion-dollar incremental TAM opportunity. Under the terms of the definitive agreement, Cadence will pay approximately $1.24B for the transaction, with 60% of the consideration to be paid in cash and 40% to be paid through the issuance of Cadence common stock to current BETA CAE shareholders. In conjunction with the transaction, Cadence expects to obtain new debt financing to fund a portion of the cash component of the purchase price. Cadence plans to use free cash flow generated by its existing operations to rapidly pay down debt incurred to fund the transaction, while also maintaining share repurchases. Increasing system complexity and time-to-market pressures from accelerating mechanical and electrical hyperconvergence, along with the digital transformation in multiple industries, are driving the need for multiphysics simulations early in the design cycle. Over the past few years, Cadence has expanded its system analysis portfolio to build out a comprehensive multiphysics platform including electromagnetics, electrothermal and computational fluid dynamics CFD solutions, and with BETA CAE, Cadence will enter structural analysis, the largest system analysis segment...The acquisition is expected to close in the second quarter of 2024, subject to receipt of regulatory approvals and other customary closing conditions. BETA CAE has annual revenue of about $90M, and Cadence expects BETA CAE to contribute approximately $40 million to 2024 revenue. Cadence expects the transaction to be approximately 12 cents dilutive to its 2024 earnings per share and to become accretive in 2025 , based on Cadence's debt repayment and share repurchase plans.

09:19 EST Twilio announces additional $2B share repurchase program - Concurrent with the conclusion of the operational review of segment, Twilio announced that its board has authorized an additional $2B share repurchase program expiring on December 31, which is in addition to the $1B program previously authorized by the board in 2023. To date, Twilio has completed almost $800M of repurchases from the initial program and is targeting to complete both programs, representing further share repurchases of approximately $2.2B, between now and the end of 2024.

09:18 EST Target sees 300 new store openings over next decade - Expects to continue to invest in supply chain and technology. Says 10 supply chain facilities in the pipeline and expected to be operational in next decade. Says launching new membership program, "Target Circle 360," next month. Comments taken from Q4 earnings conference call.

09:15 EST Wrap Technologies announces BolaWrap full deployment of Detroit PD's CIT - Wrap Technologies announced a 20 unit expansion order for BolaWrap 150 remote restraint devices by the Detroit Police Department, PD, following a successful initial partial deployment in 2023. The aim of this purchase was to support the Detroit PD's Crisis Intervention Team, CIT, which is tasked with responding to calls relating to individuals in mental health crises. "This expanded deployment represents a significant milestone in the adoption of a 'no-harm' inspired public safety technique in one of the nation's largest and most dangerous, urban areas," said Scot Cohen, CEO of Wrap Technologies. "The Detroit Police are at the national forefront of higher purpose policing by equipping their officers with the first new police tool to be added to any belt in the last 30 years, and we are honored to be working alongside them."

09:15 EST Virginia DOT awards new contract to Iteris for 'smart mobility initiative' - Iteris announced it has been awarded a new contract by the Virginia Department of Transportation for a statewide smart mobility initiative...This contract involves operations planning and on-call services support. Under the terms of the contract, Iteris, with input and collaboration from VHB, Kimley-Horn, and Prime AE, will develop a Traffic Operations Strategic Plan, TOSP, for the state of Virginia, which will encompass all programs within the scope of Traffic Operations and will define a path forward for the future of VDOT's Traffic Operations Program.

09:14 EST Firefly Neuroscience's white paper unveils BNA platform's impact - Firefly Neuroscience announced the findings presented in a 2023 white paper "Brain Network Analytics in the Psychiatric Practice: Real-Life Data Analysis" by Charlotte Baumeister, Ph.D., with analysis by Offir Laufer, Ph.D. Firefly has entered into an agreement to merge with WaveDancer, subject to the approval of the stockholders of Firefly and WaveDancer. Jon Olsen, Chief Executive Officer of Firefly, said, "Our BNA Platform, powered by cutting-edge AI, automizes EEG analysis to provide comprehensive insights into brain function. With the potential to revolutionize disease management, enhance treatment outcomes, and improve the overall well-being of patients with mental illnesses and cognitive disorders, we believe the BNA(TM) Platform can have a transformative impact. Backed by real-world clinical data from 2,253 patients, the societal ramifications are clear - the potential to usher in a new era of improved patient outcomes."

09:12 EST Concentrix appoints Peterson as EVP, Chief Product Officer - Concentrix Corporation (CNXC) announced the arrival of Ryan Peterson as Executive Vice President, EVP, and Chief Product Officer. Ryan will join the Concentrix Global Executive Team and report directly to Chris Caldwell, President and CEO. Peterson was most recently at Amazon (AMZN) Web Services, as a Global Leader of the Customer Experience application.

09:11 EST Cheche Technology expands Sinopec partnership for digital insurance solution - Cheche has expanded its partnership with Sinopec Easy Joy Sales, a subsidiary of Sinopec, to provide embedded auto insurance services in over 5,000 of Sinopec's gas stations nationwide. Sinopec Easy Joy operates Sinopec's non-oil businesses, with a nationwide retail footprint that includes over 30,000 gas stations, 28,000 convenience stores, and 10,000 auto care centers. Under the partnership, Sinopec Easy Joy will leverage Cheche's digital infrastructure and experience in scenario-based auto insurance services to empower service station personnel to deliver and enhance value-added services, including auto insurance issuance, renewals, and other related products.

09:11 EST Edible Garden announces appointment of Curnutt as SVP of Business Development - Edible Garden AG Incorporated announced that Chanida Curnutt has been appointed Senior Vice President, SVP, of Business Development and Compliance. Before joining Edible Garden, Curnutt was an independent advisor to Oventure Investments Group

09:09 EST Nektar initiates Phase 2b clinical study of alopecia areata candidate - Nektar initiated its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata. Rezpegaldesleukin is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional T reg cells and engaging multiple immunoregulatory pathways. Nektar expects topline data from this study expected in the first half of 2025. Initial results from the study are anticipated in the first half of 2025.

09:08 EST Silk Road Medical expands TCAR portfolio with launch of tapered ENROUTE system - Silk Road Medical announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States. This launch expands upon the company's prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization procedure to patient anatomy. "As pioneers in stroke prevention, our product development efforts are focused on extending our lead in the minimally invasive treatment of carotid artery disease," said Chas McKhann, Chief Executive Officer of Silk Road Medical. "New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road's carotid solutions. We are pleased to bring this portfolio expansion to market as part of our commitment to offering a diverse toolkit for physicians, allowing them to address individual patient anatomy."

09:07 EST Scilex sets launch price of $595 per 150mL bottle of Gloperba - Scilex Holding Company announced expected plans to launch Gloperba, its novel liquid colchicine formulation, in the first half of 2024 with a launch price of $595 per 150ml bottle. Gloperba is the only FDA approved liquid formulation of colchicine for the prophylaxis of acute gout flares. Over 70% of gout patients have chronic kidney disease and many suffer from gastrointestinal sensitivity, necessitating a lower dose of colchicine than the standard 0.6 mg tablet or capsule. Gloperba is expected to be the first liquid colchicine formulation that allows healthcare providers to prescribe precision dosing in at-risk patient populations, and thereby help mitigate against severe toxicity in patients.

09:06 EST Opko Health's ModeX presents results from Phase 1 study of SAR441236 - ModeX Therapeutics, an OPKO Health company, announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus, at the 2024 Conference on Retroviruses and Opportunistic Infections in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection. "This study represents a milestone in the development of multispecific antibodies, demonstrating key parameters of pharmacokinetics and safety. The study's full data set inform our ongoing development of multispecific antibodies to prevent or treat HIV infection," said Dr. John Mascola, Chief Scientific Officer of ModeX. "Existing oral antiretroviral therapies are a powerful tool in the fight against HIV, but multispecific antibodies offer long-lasting preventative and treatment options against a broad swathe of variants, with the possibility of activating the immune system against the latent virus population to effect a functional cure."

09:04 EST DaVita expands operations in Brazil and Colombia, enters Chile and Ecuador - DaVita has agreed to terms on the expansion of its international operations in Brazil and Colombia, and its entry into Chile and Ecuador. The deal involves four separate acquisitions from Fresenius Medical Care for a total purchase price of $300M. The transaction in Chile closed. The transactions in Ecuador, Colombia and Brazil remain subject to each country's respective anti-trust and regulatory approval processes, which are each expected to be completed at various times during 2024. Upon completion of the transactions, the company will have more than 15,000 DaVita teammates providing clinical care to more than 60,000 patients in more than 270 clinics. As a result, DaVita would become the largest dialysis services provider in Latin America.

08:55 EST Amprius announces high-volume silicon anode cell shipment to KARI - Amprius Technologies announced it completed a high-volume shipment of SiMaxx cells to the Korean Aerospace Research Institute or KARI, known as the aeronautics and space agency of South Korea, further strengthening Amprius' position as the premier global battery solution for HAPS applications. "This partnership with KARI achieves several of our goals, including validating our innovative technology on a global scale and highlighting our ability to provide industry-leading HAPS solutions," said Dr. Kang Sun, CEO of Amprius Technologies. "We remain committed to delivering unmatched battery performance for the future of aerospace technology and look forward to our continued efforts in collaboration with the KARI team in the future..."Our pursuit of groundbreaking stratospheric missions demands cutting-edge energy solutions to meet stringent performance criteria," said Seung-jae Hwang, Project Manager of KARI's Solar HALE project. "Integrating Amprius' ultra-high-energy density batteries into our solar-powered electrical aerial vehicle allows us to significantly enhance the overall performance and viability of our missions while redefining the cargo capability and extending flight durations in the stratosphere."

08:52 EST Mullen Automotive's Bollinger names next 2 dealers in 7 states, 11 locations - Mullen Automotive announces its subsidiary, Bollinger Motors, has named the next two dealership groups, spanning seven states and 11 locations, as Bollinger rolls out its commercial electric truck line, beginning with the Bollinger B4 Chassis Cab in the second half of 2024. The dealership groups are: Nacarato Truck Centers - 10 locations in Florida, Georgia, Kentucky, Maryland, Tennessee and Virginia. Nuss Truck and Equipment - one location in Minneapolis, Minnesota.

08:49 EST Western Digital provides update on separation, appoints executive leadership - Western Digital provided an update on its previously announced plan to separate into two independent, publicly traded companies. On track for the second half of calendar year 2024, progress towards the completion of the separation is underway with transactional projects including global legal entity establishment, customer and supplier contract transfers, final stage preparation for government filings, and initial executive leadership appointments for both HDD and Flash companies post-separation. Announced on October 30, 2023, Western Digital plans to separate its HDD and Flash businesses, creating two independent, public companies with market-specific, strategic focus. In the current phase of its separation process, the company is making progress in a broad scope of projects critical to completing the transaction as scheduled. Currently, Western Digital's separation teams are establishing legal entities in the 18 countries where operations are located, preparing independent company financial models, finishing final preparations for SEC and IRS filings, conducting a contract assignment process for global customers and suppliers, and designing company-wide organizational structures for both companies. Establishing the executive leadership team for the Flash spinoff company also is progressing with Goeckeler today appointed CEO Designate. Irving Tan, currently Executive Vice President, Global Operations at Western Digital, will step into the CEO role for the remaining standalone HDD company to continue operating as Western Digital. Western Digital will continue to provide updates throughout the separation process as key projects progress.

08:36 EST Vir Biotechnology completes Phase 2 SOLSTICE clinical trial ahead of schedule - Vir Biotechnology announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta, CHD, virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts - one evaluating tobevibart given every 2 weeks and the other evaluating the combination of tobevibart and elebsiran given every 4 weeks. Initial data are expected in the second quarter of 2024. "The swift completion of enrollment ahead of expectations reflects the strong patient and physician interest being generated, and the urgent need for new treatment options for the millions of underserved hepatitis delta patients," said Carey Hwang, M.D., Ph.D., Vir's Senior Vice President, Clinical Research. "We are proud of the continued progress towards our goal of developing a safe and efficacious chronic therapy to address the significant treatment gap and look forward to reporting additional data on these participants this year."

08:35 EST Starbucks shareholder issues statement, withdraws director nominations - The Strategic Organizing Center, or SOC, a shareholder of Starbucks, issued the following statement: "The SOC launched our campaign for change at Starbucks this past November because we believed the Company's response to its employees' attempts to unionize was misguided. In our view, Starbucks' strategy - overseen by the Board of Directors (the "Board") - had materially damaged the value of the Company's brand and negatively impacted its shareholders, partners and customers. Last Tuesday, Starbucks and Workers United announced that the two sides had agreed to work together on a path forward to reach collective bargaining agreements for represented stores and partners, the resolution of litigation, and a fair process for workers to organize. Starbucks also took the significant step of providing employees represented by Workers United with the May 2022 benefits, including credit card tipping. As was widely noted, this agreement represents a potentially 'huge shift' in Starbucks' labor relations strategy and a 'major step forward for all involved. Since the announcements, we have had meaningful dialogue with a number of other shareholders. Based on these discussions, we believe that by and large shareholders are optimistic the Company has committed to these changes in good faith and intends to begin to repair its relationship with its workers, which will ultimately enhance performance and shareholder value. We also believe Starbucks' establishment of its Environmental, Partner and Community Impact Board Committee represents an important governance reform, one which we hope will increase board oversight and performance on Starbucks' partner-related issues. While we continue to believe that our three exceptionally qualified nominees - Maria Echaveste, Hon. Wilma Liebman, and Hon. Josh Gotbaum - would be additive to the Starbucks Board, we feel that now is the time to acknowledge the progress that has been made and to allow the Company and its workers to focus on moving forward. As such, we are withdrawing our director nominations. We think it's imperative that shareholders continue to monitor the Board's performance and Starbucks' approach to labor relations issues in the coming months - and we plan to continue to hold the Company accountable going forward. We would like to thank our nominees, the shareholders we engaged with, and everyone involved with our campaign. We are truly hopeful that the commitments made and steps taken last week will result in Starbucks returning to the right path, and the Company being able to fulfill its vast potential for all its stakeholders."

08:35 EST Ree Automotive selected by Airbus UpNext - REE Automotive has been selected by Airbus UpNext, wholly-owned innovation subsidiary of Airbus SE (EADSY), to provide technological know-how based upon its REEcorner and full-by-wire control systems. "Our fully-by-wire technology was carefully selected by Airbus UpNext to support their need in a research & technology demonstrator," said Tali Miller, Chief Business Officer of REE. "This contract is a recognition for our fully-by-wire technology."

08:33 EST Roche, Alnylam report KARDIA-2 study met primary endpoint - Roche (RHHBY) and Alnylam (ALNY) announced that the Phase II KARDIA-2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension met its primary endpoint. People with mild to moderate hypertension treated with zilebesiran added to a standard of care hypertension medication experienced a clinically and statistically significant reduction in systolic blood pressure at month three. Zilebesiran added to a standard of care demonstrated an encouraging safety and tolerability profile. The Phase II KARDIA-2 trial results will be presented as a late-breaking abstract at the 2024 American College of Cardiology Annual Scientific Session April 6-8, the companies said. "With twice-yearly dosing in combination with standard of care medication, zilebesiran has strong potential to sustain lower blood pressure and reduce the risk of stroke, heart attack and death that can result from inadequate treatment," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. "We look forward to continuing the zilebesiran Phase II study programme with Alnylam as we seek to provide transformative impact for millions of people living with uncontrolled hypertension.''

08:32 EST Telomir Pharmaceuticals announces Roizen to increase role at company - Telomir Pharmaceuticals announced that Michael Roizen, MD, a leader in age-related medicine and an existing advisor to the Company, will be increasing his role in the coming months as a Special Advisor on Age Reversal.

08:31 EST Ballard Power announces 15 MW order for stationary power market - Ballard Power Systems announced an order for 15 megawatts of fuel cell systems from a UK-based company specializing in renewable off-grid power generation. Ballard expects to deliver 150 x FCmove-HD+ 100 kW systems beginning in late 2024 and continuing through 2025. The current order of 15 MW of fuel cell systems follows prior cumulative orders for roughly 5 MW of fuel cell systems from this customer, illustrating substantial growth in Ballard's supply relationship and the proven performance of Ballard's fuel cell technology in stationary power applications. The purchase order is the first order under a new multi-year supply agreement. The agreement also provides the customer an option to purchase up to an additional 296 systems by March 2026, which, if fully exercised, would bring the total number of systems ordered to 446.

08:26 EST NextCure publishes preclinical data on function of FLRT3 - NextCure announced the publication of a manuscript titled "The FLRT3-UNC5B Checkpoint Pathway Inhibits T Cell-Based Cancer Immunotherapies" in the journal Science Advances, published by the American Association for the Advancement of Science. The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects. Axon guidance molecules that regulate axonal growth in the developing nervous system have been shown to play a role in the regulation of immune and inflammatory responses. These data demonstrate that cancer cells can exploit AGM protein-protein interactions to evade T cell anti-tumor immunity by acting as checkpoint inhibitors to suppress T cell responses and immune function. Using a genetic screen called "gain of function," the study demonstrated that FLRT3, an AGM, has a novel function as an inhibitor of T cell activity through UNC5B, an axon guidance receptor that also is expressed on T cells and upregulated on activated human T cells.

08:23 EST Clubhouse Media announces HoneyDrip.com growth results for February - Clubhouse Media Group announced that HoneyDrip.com has seen month over month growth, continuing into February 2024. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. HoneyDrip.com has experienced rapid growth in four main categories during the month of February 2024 alone: 1) Active performers on the site increased by 3%; 2) Content posts to be sold increased by 5%; 3) Active users increased by 5%; 4) Applications from creators wishing to join the site increased by 2%

08:21 EST 3D Systems announces additional partial repurchase of senior notes - 3D Systems announced that it has entered into separate, privately negotiated repurchase agreements with a limited number of holders of its 0% Convertible Senior Notes due 2026 to repurchase $110 million aggregate principal amount of the Notes at approximately a 22% percent discount to par value. The debt repurchase will be paid in cash from the Company's balance sheet. President and CEO Dr. Jeffrey Graves stated, "Today's announced additional repurchase of $110 million of our 2026 notes at a significant discount once again demonstrates our approach to proactive liability management and disciplined execution in the current environment. Over the last three months, we have opportunistically reduced our 2026 maturity by over 50% to reinforce the strength of our balance sheet, while we continue to maintain one of the strongest levels of cash reserves in the industry. Today's transaction in combination with our targeted initiatives to drive enhanced gross margins and cost efficiencies reinforce our belief that 3D Systems is well positioned to deliver on the bright long-term future ahead."

08:17 EST Akari Therapeutics, Peak Bio announce definitive agreement to merge as equals - Akari Therapeutics (AKTX) and Peak Bio (PKBO) announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages. An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations. Under the terms of the agreement, Peak stockholders will receive a number of Akari ordinary shares for each share of Peak stock they own, as determined on the basis of the exchange ratio described in the agreement. The exchange is expected to result in implied equity ownership in the combined company of approximately 50% for Akari shareholders and approximately 50% for Peak stockholders on a fully-diluted basis, subject to adjustment under certain circumstances, including based on each party's relative level of net cash at the closing of the proposed transaction. Hoyoung Huh, M.D., Ph.D. is expected to serve as incoming Chairman of the Board of the combined entity. Dr. Huh is currently Chairman of the Board of Directors at Pliant Therapeutics and co-founder of BridgeBio Pharma. The post-merger Board of Directors will consist of three directors selected by each company and one independent director jointly selected.

08:15 EST Perspective Therapeutics acquires CGMP-compliant manufacturing facility - Perspective Therapeutics, (CATX) announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Previously operated by Lantheus Holdings (LNTH), this 11,500 square foot facility, located in Somerset, New Jersey, has operated in compliance with both Part 212 and Part 211 of Title 21 of the Code of Federal Regulations in the U.S., meeting Current Good Manufacturing Practice, cGMP, requirements. As a cGMP compliant facility, Perspective intends to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with targeted alpha therapies.

08:13 EST Joby begins hiring to support operations in newly acquired Ohio facility - Joby Aviation announced it has acquired an existing facility at Dayton International Airport and begun hiring in support of the Company's initial manufacturing operations in Dayton, Ohio...Joby's pilot production line in Marina, California, with two of the company's prototype aircraft. Joby Aviation photoThe facility acquired by Joby will be fitted out to support initial manufacturing operations in Dayton, which are expected to begin later this year. The facility will be used for the manufacturing of aircraft parts in support of Joby's Pilot Production Line in Marina, California...Joby announced in September 2023 that it had selected Dayton, Ohio, as the location for its scaled manufacturing facility, capable of producing up to 500 electric vertical take-off and landing or eVTOL, aircraft per year, with plans to invest up to $500M and create up to 2,000 high-quality, clean manufacturing jobs in the region. Joby's electric air taxi is designed to carry a pilot and four passengers at speeds of up to 200 mph, offering high-speed mobility with a fraction of the noise produced by helicopters and zero operating emissions.

08:12 EST QuickLogic awarded eFPGA IP contract for TSMC N12e process technology - QuickLogic was selected by a large multi-national company for eFPGA IP targeting the TSMC N12e, 12nm process. IP delivery for this contract is scheduled for FY24. This design is for a new, ultra-low-power SoC that leverages the benefits of AI for a variety of commercial and industrial IoT applications.

08:10 EST CervoMed announces presentation of data from AscenD-LB Phase 2a trial - CervoMed announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies, demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB. These data will be featured in a poster presentation at the 18th International Conference on Alzheimer's and Parkinson's Diseases. "The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB," said John Alam, MD, Chief Executive Officer of CervoMed. "The exciting data from UCL are consistent with the mechanism of action of neflamapimod in the treatment of dementia with Lewy bodies, where axonal transport defects related to the microtubule-associated protein tau in basal forebrain cholinergic neurons are an important pathogenic driver. Moreover, their findings provide a strong scientific rationale for evaluating neflamapimod as a treatment for certain forms of frontotemporal dementia."

08:09 EST Visa and Western Union announce expanded cross-border collaboration - Visa (V) announced a 7-year agreement with Western Union (WU). Under the new deal, Western Union customers will be able to send money to their family and friends' eligible Visa cards and bank accounts in 40 countries across five regions. The agreement encompasses card issuance, Western Union's integration with Visa Direct, and value-added services delivery including risk products. Western Union customers will also be able to receive Visa prepaid cards in select markets offering an innovative solution that bridges the physical and digital world. "People rely on remittances to send lifeline payments to their loved ones overseas. When we consider the urgency and need for accessibility, secure payment options with added convenience can make all the difference," said Chris Newkirk, Global Head of Commercial & Money Movement Solutions, Visa. "Visa's global scale and Western Union's digital capabilities are revolutionizing how customers send funds around the world. We are proud to offer more people fast and efficient solutions for cross-border payments."

08:08 EST Allergan Aesthetics announces FDA approval of JUVEDERM VOLUMA XC - Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of JUVEDERM VOLUMA XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21. JUVEDERM VOLUMA XC is the first and only hyaluronic acid dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.

08:08 EST BioAffinity Technologies reports accelerating sales growth of CyPath Lung tests - BioAffinity Technologies reported accelerating growth of 375% in CyPath Lung tests ordered and processed over the past three months as compared to the previous three months. CyPath Lung is a noninvasive test to detect early-stage lung cancer. BioAffinity Technologies is on target to meet its sales forecast for the previously announced limited test market launch in Texas designed to refine future positioning and strategic insight for CyPath Lung in preparation for expanding to the national market.

08:06 EST Trinity Capital provides $50M in equipment financing to Electric Hydrogen - Trinity Capital announced the commitment of $50M in equipment financing to Electric Hydrogen, a manufacturer of electrolyzer systems that produce green hydrogen for critical industries. In 2023, Electric Hydrogen completed a Series C equity raise of $380M, bringing the total capital raised by the company to more than $600M. The new equipment finance facility from Trinity is a key piece of the financing behind Electric Hydrogen's gigafactory in Devens, MA which begins production in Q2.

08:06 EST The9 to acquire AIGC-driven digital human SaaS platform ShenMa - The9 signed a legally binding term sheet with Shenma to purchase 51% shares of Shenma by cash and issuance of The9's restricted shares. The9 will pay cash consideration of $1M and will issue restricted Class A ordinary shares to Shenma or its shareholders with the value of $14.3M. The value of each share will be determined by the average closing price of The9's ADSs, each representing 300 Class A ordinary shares of The9, for a period of 20 trading days prior to the signing of the definitive agreement. The restricted Class A ordinary shares to be issued to Shenma will be subject to lock-up conditions and will only be released according to this schedule: when the market capitalization of The9 reaches $200M, 33,938,400 Class A ordinary shares will be released from the lock-up; when the market capitalization of The9 reaches $500M, 13,575,300 shares will be released from the lock-up, and when market capitalization of The9 reaches $1B, 6,787,800 shares will be released from the lock-up. The rest of the restricted Class A ordinary shares will be released when Shenma completes a qualified IPO and its shares owned by The9 become freely tradable in the open market. Shenma developed and operates Shenma.io, a digital human SaaS platform driven by artificial intelligence-generated content - AIGC -. The platform has 350,000 registered users, 150,000 short video scripts model library, 9,000 digital human creators and different brand customers.

08:05 EST Dell Technologies, Crowdstrike expand partnership - Dell Technologies (DELL) and CrowdStrike (CRWD) announced an expanded strategic partnership to deliver Dell's Managed Detection and Response services with the industry-leading AI-native CrowdStrike Falcon XDR platform, helping customers defend against increasingly complex cyberattacks. Dell Managed Detection and Response is now available for global customers with the CrowdStrike Falcon XDR Platform as a direct solution and through channel partners.

08:03 EST Analog Devices announces FDA 510(k) clearance of Sensinel CPM System - Analog Devices announced U.S. FDA 510(k) clearance and the commercial launch of the Sensinel Cardiopulmonary Management System. The compact wearable device is a non-invasive, remote management system that captures cardiopulmonary measurements for chronic disease management such as heart failure. It is the first FDA clearance the company has received in its 59-year history. ADI's Sensinel CPM System is now commercially available.

07:55 EST Momentus gets NASA contract to provide flight/payload integration services - Momentus announces that it has been awarded a NASA indefinite-delivery/indefinite-quantity or ID/IQ, base contract award with a performance period of five years to provide flight and payload integration services to advance technologies and procedures for operating in space. Under the ID/IQ contract awarded by NASA, Momentus is among 15 companies selected that are eligible to receive task or delivery orders to provide in-space transportation services, including propulsion systems and orbital transfer capabilities, to facilitate the deployment of satellites, payloads, and scientific instruments. "We are honored to be selected by NASA for this important opportunity to support the United States' efforts in space," said John Rood, CEO of Momentus. The contracts will be managed by NASA's Flight Opportunities program, in collaboration with the Small Spacecraft Technology program, both part of the agency's Space Technology Mission Directorate. Momentus' Vigoride vehicle offers flexible and reliable transportation solutions for a wide range of mission profiles at various orbits. The company's technology includes water plasma thrusters, which are safer and more environmentally friendly than traditional chemical propulsion systems and flexible solar arrays to allow deployment and retraction of critical power generation capabilities. .

07:51 EST Baxter discloses recent talks with PE investors on potential sale of Kidney Care - In a regulatory filing yesterday, Baxter International provided an update on the planned separation of its Kidney Care business. "Consistent with Baxter's commitment to evaluate strategic options in the interest of maximizing stockholder value, Baxter disclosed that it has been in recent discussions with select private equity investors to explore a potential sale of the Kidney Care asset in lieu of the proposed spinoff of that business. No final decision on the separation structure has been made and Baxter continues to make progress on the previously announced proposed spinoff of the Kidney Care business. Regardless of the separation structure ultimately selected, Baxter has expressed its commitment to separating the Kidney Care business in the second half of 2024," the company stated. Reference Link

07:40 EST Whitestone REIT board declares monthly cash dividend of 4.125c per share - Whitestone REIT announced that its Board of Trustees has declared a monthly cash dividend of 4.125c per share on the Company's common shares and operating partnership units for the second quarter of 2024. The dividend increase represents a quarterly amount of 12.375c per share, and an annualized amount of 49.5c per share. "We are focused on delivering consistent growth, driven by very strong leasing spreads and record occupancy, as we will share on our upcoming 4th quarter 2023 earnings call," said Dave Holeman, Whitestone's CEO. "Our second quarter dividend represents a 3% increase from the first quarter, a reflection of the board's confidence in Whitestone's earnings growth trajectory and ability to strengthen the balance sheet while simultaneously growing the dividend."

07:37 EST Lava Therapeutics announces clinical development milestone achieved by Pfizer - LAVA Therapeutics (LVTX) announced that Pfizer (PFE) has achieved a clinical development milestone for PF-08046052, prompting the first milestone payment of $7 Million to LAVA. LAVA granted Seagen, which was acquired by Pfizer in December 2023, a worldwide, exclusive license to PF-08046052 in September 2022. "We are very pleased with the initiation of clinical development by Pfizer of PF-08046052, formerly SGN-EGFRd2/LAVA-1223. We have always viewed this molecule with excitement about its potential in oncology. Achievement of this milestone is another important step in realizing the potential of LAVA's Gammabody(R) platform. As the Phase 1 study advances, we look forward to continued clinical progress and future data readouts," said Stephen Hurly, President and Chief Executive Officer of LAVA.

07:34 EST A SPAC I Acquisition and NewGenIvf shareholders approve business combination - A SPAC I Acquisition and NewGenIvf , a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, and announced that the previously announced a business combination was approved at an extraordinary general meeting of A SPAC I on March 4. The Business Combination is expected to close once all closing conditions have been met. The combined company will be named "NewGenIvf Group Limited" and its shares and warrants are expected to begin trading on the Nasdaq Capital Market under the tickers "NIVF", and "NIVFW", respectively. NewGen is a family of fertility clinics primarily serving patients in Southeast Asia. The company currently provides fertility services across three jurisdictions, namely Thailand, Cambodia, and Kyrgyzstan. Upon business combination closing, the combined company will be named NewGenIvf Group, and will be the only listed Asian company offering legal surrogacy services for couples as well as single parents, including the LGBTQ+ community, according to China Insight Consultancy. The company utilizes exclusive access to licensed technologies, including MicroSort. The transaction sets NewGen's enterprise value at approximately $50M.

07:28 EST 2seventy bio: Close of asset sale to Regeneron seen in 1H24 - FDA decision on the sBLA for 2seventy bio's (TSVT) Abecma in 3L multiple myeloma is anticipated following the ODAC meeting on March 15...Close of the asset sale to Regeneron (REGN) is expected in the first half of 2024.

07:22 EST Gilat Satellite selected by Safran Passenger for in-flight connectivity program - Gilat Satellite Networks announced that it was selected by Safran Passenger Innovations for a strategic, multimillion-dollar in-flight connectivity, IFC, program. Gilat's Wavestream subsidiary will develop, qualify, and produce a new line of Ku band Power Supply Unit products to support Safran's Ku-band electronically steerable antenna, bolstering further growth in the IFC market. "Safran decided to work with Gilat's Wavestream subsidiary on this project because of their extensive experience in building and qualifying commercial-grade aeronautical equipment for satellite communications," said John Andrews, Vice President, Connectivity at Safran Passenger Innovations. "With this new Wavestream KPSU product from Gilat, we will soon be able to expand our product portfolio with a new ESA IFC terminal, for which we see high demand in the market."

07:20 EST BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units covering an aggregate of 11,300 shares, of BioCryst common stock. The options and RSUs were granted as of February 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

07:16 EST AbbVie makes milestone payment to Dragonfly after dosing in solid tumor trial - AbbVie made a milestone payment to Dragonfly Therapeutics, a clinical stage biotechnology company developing novel immunotherapies, following dosing of the first patient in a clinical trial to evaluate ABBV-303, a solid tumor targeting TriNKET. ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly's platform technology to enter the clinic, and the first AbbVie-licensed TriNKET drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie's budigalimab in solid tumors.

07:12 EST Regenxbio's RGX-202 shows initial efficacy in Duchenne - Regenxbio reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy ages 4 to 11 years old, including RGX-202 microdystrophin expression from dose level 2 and video of trial clinic assessments demonstrating initial evidence of strength and functional improvement. As of February 28, RGX-202 has been well tolerated with no drug-related serious adverse events in five patients, aged 4.4 to 12.1 at dose level 1 and 2. Time of post-administration follow up ranges from approximately seven weeks to over eleven months. All patients who reached three-month follow-up have completed the immunosuppression regimen per study protocol. In the first patient, aged 12.1 years, who received RGX-202 at dose level 2, RGX-202 microdystrophin expression was measured to be 75.7% compared to control at three months. A reduction from baseline in serum creatinine kinase levels of 77% was observed at ten weeks. All four patients, across both dose levels, who completed three-month trial assessments indicate encouraging increases in expression of RGX-202 microdystrophin and reduction from baseline in serum CK levels, supporting evidence of clinical improvement. Among patients aged 8 to 11 years old at screening, RGX-202 microdsytrophin expression levels at three months following RGX-202 administration was higher in dose level 2. New recordings of the trial clinic assessments and home videos illustrate patients treated with RGX-202 are demonstrating initial evidence of strength and functional improvement. Regenxbio expects to make a pivotal dose determination in mid-2024. The company also expects to share strength and functional assessment data for both dose levels and the initiation of a pivotal trial in the second half of 2024.

07:10 EST Aya Gold & Silver announces drill results at Zgounder Silver Mine - Aya Gold & Silver announces high-grade silver drill results from its at-depth drill exploration program at the Zgounder Silver Mine in the Kingdom of Morocco. "Today's drilling results including holes ZG-SF-23-084 and ZG-SF-23-092 continue to confirm high-grade silver mineralization near the granite contact," said Benoit La Salle, President & CEO. "Notably, the latter results are hosted within the rhyolite, which was previously believed to be barren, opening a new area for exploration. Four underground rigs are now mobilized with the objective of expanding mineral resources at depth and delivering value for all stakeholders."

07:09 EST Cartesian establishes new corporate headquarters, manufacturing facility - Cartesian Therapeutics announced its plans to transition its corporate headquarters to Frederick, Maryland. The approximately 20,000 square foot state-of-the-art current good manufacturing practice compliant facility has clinical and commercial manufacturing scale capabilities designed to support the Company's maturing pipeline of innovative mRNA cell therapies for the treatment of autoimmune diseases. "Our new headquarters and manufacturing facility will provide us with the infrastructure to support our next phase of growth while allowing us to remain in the vibrant I-270 Biotech Corridor community," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "Importantly, we believe the new facility will allow us to scale our wholly-owned, in-house cGMP manufacturing capabilities for late-stage clinical and commercial supply of our mRNA cell therapy product candidates, while continuing to maintain control over product quality and production. We look forward to relocating to Frederick as we continue to work toward our mission of expanding the reach of cell therapy to patients with autoimmune diseases."

07:07 EST KKR appoints Ruchir Swarup as Partner and Chief Information Officer - KKR announced the appointment of Ruchir Swarup as a Partner and Chief Information Officer, effective immediately. In this role, Mr. Swarup will be responsible for driving KKR's technology strategy and vision. Based in New York, Mr. Swarup will lead the firm's efforts to embrace new technologies and scale existing technology to create efficiencies and reduce risk across the firm. . Swarup brings significant investment technology experience across both public and private markets. He joins KKR from Addepar...

07:06 EST Old Dominion reports February LTL revenue per day increased 1.2% YoY - Old Dominion Freight Line reported certain less-than-truckload "LTL" operating metrics for February 2024. Revenue per day increased 1.2% as compared to February 2023 due to an increase in LTL revenue per hundredweight that was slightly offset by a 3.0% decrease in LTL tons per day. The change in LTL tons per day was attributable to a 3.2% decrease in LTL weight per shipment that was partially offset by a 0.2% increase in LTL shipments per day. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight, excluding fuel surcharges, increased 3.7% and 7.1%, respectively, as compared to the same period last year. Marty Freeman, President and Chief Executive Officer of Old Dominion, commented, "Our revenue results turned slightly positive in February but continue to reflect softness in the domestic economy. Our LTL shipments per day also increased slightly as compared to February 2023 while our yield metrics continued to improve. The increase in our LTL revenue per hundredweight was supported by a favorable pricing environment and our ongoing ability to deliver superior service at a fair price. We believe our value proposition is unmatched in the marketplace, which provides us with a tremendous opportunity to win market share and produce strong profitable growth once the macroeconomic environment begins to improve."

07:03 EST Carrier Global sells industrial fire business to Sentinel Capital for $1.425B - Carrier Global entered into a definitive agreement to sell its Industrial Fire business, which includes brands Det-Tronics, Marioff, Autronica and Fireye, to Sentinel Capital Partners for an enterprise value of $1.425B. Carrier continues to prepare for the last of its four announced business exits - its combined commercial and residential fire businesses. Carrier expects net proceeds from the transaction to exceed $1.1B and intends to use the proceeds to pay down debt. The company anticipates resuming share repurchases as it returns to approximately 2X net leverage by the end of 2024. Closing is expected in Q3 and is subject to regulatory approvals and customary closing conditions.

07:01 EST Tiziana Life Sciences to present at AD/PD of nasal anti-CD3 in Alzheimer's - Tiziana Life Sciences announced that it will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer's and Parkinson's disease at AD/PD, March 5-9, 2024. "With the focus on effective Alzheimer's disease treatments and we have the potential to be a novel, first in class neuroinflammatory modulator," commented Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences. "Our intranasal approach has large potential as it does not target beta-amyloid or other proteins, but focuses on the neuroinflammatory process itself, which may be complementary or synergistic with existing FDA approved treatments. The data also excitingly shows a reduction of hemorrhage and edema that occurs with ARIA."

06:52 EST MAG Silver reports preliminary 2024 Juanicipio guidance - MAG Silver reports preliminary 2024 guidance for the high-grade Juanicipio Mine jointly owned by Fresnillo plc (56%) and MAG (44%). Highlights: Robust silver head grade: As reported by Fresnillo, the project operator, silver head grade at Juanicipio is expected to range between 380 grams per tonne and 420 g/t for 2024, translating to significant silver production potential. Nameplate capacity: The plant is anticipated to operate at nameplate capacity per operating day with an effective utilization of 91%, ensuring consistent and efficient production. Technical report on track: MAG remains on schedule to publish its updated technical report by the end of Q1 2024, providing more definitive guidance and solidifying our outlook for the Juanicipio Mine "Following a very successful start-up and ramp-up phase in 2023, the Juanicipio Mine is now operating at steady-state with robust silver grades and operations beginning to benefit from increasing efficiencies," said George Paspalas, President and CEO of MAG. "With the release of our updated technical report on the horizon, we're eager to paint an even clearer picture of the exciting future ahead for Juanicipio and MAG Silver."

06:43 EST Matrix Service awarded construction of oil storage ranks on West Coast - Matrix Service's subsidiary Matrix North American Construction has been awarded the engineering, procurement, and construction of three 522,000-barrel crude oil storage tanks for a long-standing client at a terminal on the West Coast. Matrix Applied Technologies will also provide geodesic domes, which help manage carbon emissions, as part of the project.

06:39 EST MarketAxess delivers record total credit ADV of $15.2B in February - Chris Concannon, CEO of MarketAxess, commented: "We delivered record total credit ADV of $15.2 billion, driven by a 14.6% increase in U.S. high-grade ADV, a 12.5% increase in emerging markets ADV, a 9.1% increase in Eurobonds ADV, and an 8.0% increase in municipal bonds ADV. Strong credit volumes quarter-to-date across several of our growth cylinders have more than offset significantly lower levels of U.S. high-yield trading activity on our platform impacted by continued low levels of credit spread volatility. The roll-out of MarketAxess X-Pro is continuing and client engagement is increasing with approximately 14% of our largest client firms active on the platform, up from 12% in January 2024."

06:15 EST Sandoz says Colin Bond to retire as CFO on June 30 - The board of directors of Sandoz announced that it proposes Mathai Mammen, M.D., Ph.D., and Michael Rechsteiner for election to its Board of Directors at the company's Annual General Meeting on April 30. At the same time, Sandoz announced that Remco Steenbergen, currently a Sandoz Board member, will become a member of the Executive Committee and take on the responsibility of Sandoz CFO as of July 1, succeeding Colin Bond who has decided to retire. Colin will remain in his role until his successor's arrival and will continue to support the Executive Committee as a senior advisor thereafter until his retirement. Following this announcement, Remco Steenbergen will not stand for re-election at the upcoming Annual General Meeting on April 30, the company noted.

06:09 EST Digihost expands bitcoin mining fleet - Digihost signed a multi-year hosting agreement with a manufacturer of digital currency mining servers. Digihost will receive an upfront deposit of approximately $1.8M along with 4,640 S19 XPs - 21.5W/TH -, which equates to approximately 14MW of hosting. The company plans to deploy these miners prior to the next Bitcoin halving. The deployment will result in an expected hash rate increase of approximately 700 PH/s, bringing Digihost's total hash rate to 2.4 EH/s. Digihost is currently the anchor subscriber to a 5MW Community Solar project located in Angola, New York. A ribbon cutting for the project is scheduled for Q3, which is when the solar credits will begin. Presently, Digihost's consolidated operating capacity across its three sites represents approximately 90MW of available power, and Digihost is mining at hash rate of 2 EH/s.

06:06 EST Apogee Therapeutics' APG777 shows positive Phase 1 results in dermatitis - Apogee Therapeutics announced positive interim Phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis, or AD, and other inflammatory diseases. Pharmacokinetic data showed a half-life of approximately 75 days across doses tested and Pharmacodynamic data showed deep and sustained inhibition of key AD biomarkers for ~3 months. Results from the trial exceeded the company's trial objectives and support the potential for APG777 to optimize exposure levels in 16-week induction and be dosed once every three or six months in maintenance. These findings represent the potential for improved clinical responses from greater exposures in induction and significantly less frequent dosing in maintenance compared to currently approved biologic therapies. APG777 was well tolerated and showed a favorable safety profile. Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule. AD is a chronic inflammatory skin disorder which can lead to sleep disturbance, psychological distress, elevated infection risk and chronic pain, all of which significantly impact quality of life. Apogee plans to advance APG777 into a randomized, placebo-controlled, 16-week Phase 2 clinical trial in patients with moderate-to-severe AD. Phase 2 AD trial is expected to initiate in the 1H of 2024 with 16-week topline data from Part A expected in 2H 2025.

05:44 EST BowFlex files for Chapter 11, enters purchase agreement with Johnson Health - BowFlex announced that it has entered into a purchase agreement with Johnson Health Tech Retail, Inc. to serve as the stalking horse bidder to acquire substantially all of the assets of the company for $37.5M in cash at the closing of the transaction, less closing adjustment amounts for accounts receivable, inventory and certain transfer taxes. In order to facilitate the sale process, the company and certain of its subsidiaries have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of New Jersey, which will provide interested parties the opportunity to submit competing offers. Additionally, subject to court approval, the company has secured a $25M facility for debtor-in-possession financing, comprised of a $9M revolving commitment and $16M term loan reflecting the roll-up of the company's pre-petition term loans of approximately $16M from Crystal Financial d/b/a SLR Credit Solutions and its affiliates, subject to court approval, to enable the company to continue operating in a normal course and meet its financial obligations to employees, vendors and its continued provision of customer orders during Chapter 11 proceedings and while executing the sale process. The DIP Facility is being provided by SLR pursuant to an amendment to the company's existing term loan credit agreement with SLR dated November 30, 2022. The company is seeking approval of the proposed transaction pursuant to Section 363 of Chapter 11 of the U.S. Bankruptcy Code, which will allow outside interested parties to submit higher or otherwise better offers. The transaction is subject to approval by the Bankruptcy Court and any other approvals that may be required by law, and other customary conditions. The asset purchase agreement with the Stalking Horse Bidder provides for standard bid protections. These protections include: the reimbursement by the company of up to $600,000 of the Stalking Horse Bidder's expenses payable under specified circumstances upon a termination of the Stalking Horse Asset Purchase Agreement; payment by the company of a breakup fee of 3.5% of the purchase price; and the company's forfeiture of the $3.75M Stalking Horse Bidder's deposit.

05:31 EST DexCom announces new CGM data, direct to Apple Watch functionality in Q2 - DexCom (DXCM) announced new clinical evidence supporting the use of Dexcom continuous glucose monitoring, or CGM, for automated insulin delivery, or AID, systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and data will be presented during Dexcom symposia and presentations at the 17th International Conference on Advanced Technologies and Treatments for Diabetes, held March 6-9, in Florence. Dexcom announced that 'direct to Apple (AAPL) Watch' functionality for Apple Watch will have a phased launch available to all G7 iOS users everywhere by the end of the second quarter of this year. The announcement means that Dexcom G7 will soon be the only CGM system that can connect directly to Apple Watch without always needing to carry an iPhone. People choosing Dexcom G7 to help manage their diabetes will have access to 'direct to Apple Watch' as soon as it launches in their country. Data from the longest prospective follow-up study to date of a cohort with established Type 1 diabetes, using the Insulet Omnipod 5 automated insulin delivery system with Dexcom G6, showed that long-term use of the AID system could safely maintain improvements in glycaemic outcomes for up to two years. Perhaps most significantly, despite the long duration of the study, event rates for severe hypoglycaemia and diabetic ketoacidosis remained low at 2.04 and 0.24 events per 100 person-years. Furthermore, real-world evidence from almost 3,000 people using a Tandem Control-IQ AID system, powered by Dexcom CGM, demonstrated lower rates for both severe hypoglycaemia and diabetic ketoacidosis over 12 months compared to historic rates. Concurrent with these lower rates, on average adult participants spent more than 70% CGM time in range, while paediatric participants achieved 60% CGM time in range. Dexcom also announced the availability, in the USA, of Dexcom G6 with Tandem Mobi, the world's smallest, durable automated insulin delivery system++. Integration with Dexcom G7 will quickly follow in the USA in the second quarter of this year. As demonstrated in multiple symposia and presentations at ATTD this year, clinical evidence continues to build demonstrating the effectiveness of Dexcom CGM use amongst people with all types of diabetes. Of particular note, Dexcom announced a first-of-its-kind study directly linking the benefits of CGM with a reduction in mortality for people treating Type 1 or Type 2 diabetes with insulin. These results indicate use of CGM may have broad-based benefits that extend beyond glucose lowering in patients with diabetes on insulin. Dexcom also unveiled new global user data analysis showing clinically meaningful reduction in HbA1c specifically for people managing their Type 2 diabetes with a GLP1 and using a CGM sensor compared to groups not using CGM. Dexcom data also showed that amongst Type 2 user populations, the more regularly a Dexcom CGM was worn, the more time a user spent within their desired glucose range. Furthermore, a qualitative study involving people treating their Type 2 diabetes with basal insulin found the visualization of glucose levels offered by Dexcom CGM improved understanding of the impact of treatment and lifestyle decisions on glucose levels, and the impact of those glucose levels on additional health issues.